During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate (ADC) payloads and targets. Read More
Adoptive cell therapy represents a major step forward in treating hematological cancers. Among its different approaches, chimeric antigen receptor natural killer (CAR-NK) cells are drawing growing interest. Read More
At the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, Bridgebio Oncology Therapeutics Inc. (BBOT) presented data on BBO-11818, a potent and selective KRAS inhibitor with activity against several KRAS mutants both in active (ON) and inactive (OFF) forms. Read More
Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to cancer treatment. Read More
Gilead Sciences Inc. has reported new compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer. Read More
From Dolly the sheep to mRNA vaccines, BioWorld has been reporting every breakthrough and challenge along the way. Our commitment to accurate, contextualized journalism has helped readers navigate this fast-evolving industry for 35 years. Join us as we celebrate the milestones that shaped biopharma and medtech, then and now. Read More
Researchers at the University of California, Los Angeles (UCLA), have developed a new type of allogeneic immune cell therapy that demonstrated potent antitumor activity against triple-negative breast cancer (TNBC) in preclinical studies. Read More
Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, orally bioavailable embryonic ectoderm development (EED) inhibitor that targets the PRC2 complex, in models of castration-resistant prostate cancer. Read More
Park City Bio LLC has prepared and tested new serotonin receptor agonists reported to be useful for the treatment of pain, inflammation, psychiatric and neurological disorders. Read More
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD). Read More
The multidrug resistance of methicillin-resistant Staphylococcus aureus (MRSA) makes it a global threat to public health, and the current first-line treatment for MRSA, the glycopeptide vancomycin, can have toxic effects on the kidney and ear. Read More
Hefei Institutes of Physical Sciences has synthesized new pyrazoleamide compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, Crohn’s, Graves, Parkinson’s disease, ischemia, sepsis, multiple sclerosis and HIV infection. Read More
Activating the glucagon-like peptide 1 receptor (GLP-1R) is the mechanism of action of most drugs currently used to treat obesity and type 2 diabetes. To enhance efficacy and reduce side effects, many groups have been developing double or triple agonists that, at the same time, also stimulate the receptors for glucagon (GCG) or glucose-dependent insulinotropic peptide (GIP). Read More
